Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation

Abstract Human herpesvirus type 6 (HHV6) is known to reactivate after hematopoetic stem cell transplantation (HSCT) and has been suggested to be associated with increased mortality and severe clinical manifestations, including graft versus host disease (GvHD). The exact etiological role of HHV6 reac...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2008-12, Vol.43 (4), p.361-366
Main Authors: de Pagter, P.J, Schuurman, Rob, Meijer, Ellen, van Baarle, Debbie, Sanders, E.A.M, Boelens, J.J
Format: Article
Language:English
Subjects:
Allergy and Immunology
Antiviral Agents - therapeutic use
Biological and medical sciences
Fundamental and applied biological sciences. Psychology
Graft versus host disease
Graft vs Host Disease
Hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - adverse effects
HHV-6
Human herpesvirus
Human papillomavirus 6 - physiology
Human viral diseases
Humans
Immunology
Infectious Disease
Infectious diseases
Medical sciences
Microbiology
Miscellaneous
Papillomavirus Infections - complications
Papillomavirus Infections - drug therapy
Papillomavirus Infections - immunology
Receptors, Complement 3d
Viral diseases
Viral reactivation
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Human herpesvirus type 6 (HHV6) is known to reactivate after hematopoetic stem cell transplantation (HSCT) and has been suggested to be associated with increased mortality and severe clinical manifestations, including graft versus host disease (GvHD). The exact etiological role of HHV6 reactivation in increased morbidity and mortality after HSCT remains unclear. This review will focus on the current available evidence of HHV6 reactivation after HSCT and its immuno-modulatory capacities, with particular emphasis on the severe complication GvHD. At present, no effective specific antiviral treatment for HHV6 reactivation has been identified. The currently available antiviral agents are outlined, as well as possible future strategies for the treatment of HHV6 reactivation. Non-toxic, specific treatment or prevention of HHV6 reactivation might improve the safety and efficacy of the HSCT procedure.
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2008.08.008